Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31490422 | 1.00 | IDO1 (0.46) | IDO1PLAUANPEPTSHRDRD3 | |
| SCHEMBL1243147 | 0.82 | PLAU (0.56) | PLAUANPEPTSHRCA1CA2 | |
| SCHEMBL6256650 | 0.77 | CYP19A1 (0.50) | TSHR | |
| SCHEMBL27766681 | 0.75 | IDO1 (0.46) | IDO1PLAUANPEPTSHRDRD3 | |
| SCHEMBL8809848 | 0.73 | IDO1 (0.35) | IDO1DRD3 | |
| SCHEMBL6300596 | 0.73 | CYP1A2 (0.46) | IDO1PLAUANPEPCA1CA2 | |
| SCHEMBL27566376 | 0.71 | MTNR1A (0.44) | TSHR | |
| SCHEMBL7458168 | 0.71 | PLAU (0.45) | IDO1PLAUANPEPCA1CA2 | |
| SCHEMBL7458173 | 0.71 | PLAU (0.45) | IDO1PLAUANPEPCA1CA2 | |
| SCHEMBL7458183 | 0.71 | PLAU (0.45) | IDO1PLAUANPEPCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112645971-B | Method for directly preparing alkyl borate compound from alkyl halide | 中国科学院兰州化学物理研究所 | 2021-12-24 | — | — | CN | claimed |
| JP-4347906-B2 | — | — | 2009-10-21 | — | — | JP | claimed |
| EP-0828848-B1 | PREPARATION OF HYDROXY COMPOUNDS BY BIOCONVERSION WITH DIOXYGENASE | AVECIA LTD (GB) | 2002-03-27 | — | — | EP | claimed |
| US-6087137-A | PREPARING OPTICALLY ACTIVE COMPOUNDS FOR USE AS CHEMICAL INTERMEDIATES IN SYNTHESIS OF DRUGS AND AGRICULTURAL CHEMICALS ESPECIALLY ENZYME INHIBITORS TARGETED TO HUMAN IMMUNODEFICIENCY VIRUS | ZENECA LIMITED (GB) | 2000-07-11 | — | — | US | claimed |
| EP-0828848-A1 | PREPARATION OF HYDROXY COMPOUNDS BY BIOCONVERSION WITH DIOXYGENASE | ZENECA LIMITED (GB) | 1998-03-18 | — | — | EP | claimed |
| WO-1996037628-A1 | PREPARATION OF HYDROXY COMPOUNDS BY BIOCONVERSION WITH DIOXYGENASE | ZENECA LIMITED (GB) | 1996-11-28 | — | — | WO | claimed |
| US-20260080976-A1 | SYSTEM AND METHODS FOR GENERATION OF FRAGMENT MODULE LIBRARIES FOR LEAD OPTIMIZATION OF PHARMACEUTICALLY ACTIVE MOLECULES | PURDUE RESEARCH FOUNDATION (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4543895-A1 | NOVEL IRON-BASED COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF, AND USE THEREOF AS CATALYSTS | Université Paris-Saclay (FR) | 2025-04-30 | — | — | EP | disclosed |
| WO-2023247697-A1 | NOVEL IRON-BASED COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF, AND USE THEREOF AS CATALYSTS | Universite Paris-Saclay (FR) | 2023-12-28 | — | — | WO | disclosed |
| CN-112645971-B | Method for directly preparing alkyl borate compound from alkyl halide | 中国科学院兰州化学物理研究所 | 2021-12-24 | — | — | CN | disclosed |
| WO-2021078132-A1 | INHIBITORS OF MTOR-MEDIATED INDUCTION OF AUTOPHAGY | SIRONAX LTD (GB) | 2021-04-29 | — | — | WO | disclosed |
| CN-112645971-A | Method for directly preparing alkyl borate compound from alkyl halide | 中国科学院兰州化学物理研究所 | 2021-04-13 | — | — | CN | disclosed |
| EP-2969007-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-0183492-B1 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR PREPARATION AND USE | Farmos-Yhtyma Oy (FI) | 1989-11-15 | — | — | EP | disclosed |
| EP-0310745-A2 | Substituted imidazole derivatives and their preparation and use | ORION-YHTYMÄ OY (FI) | 1989-04-12 | — | — | EP | disclosed |
| WO-1988008843-A2 | NEW IMIDAZOLS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1988-11-17 | — | — | WO | disclosed |
| US-4689339-A | 4-dihydroinden-2-yl-, 4-tetrahydronaphth-2-yl-, and 4-dihydrobenzofuran-2-ylimidazoles, useful to block α2 -adrenergic receptors | FARMOS YHTYMA OY (FI) | 1987-08-25 | — | — | US | disclosed |
| US-4596791-A | Containing heterocyclic fused ring | USV PHARMACEUTICAL CORP. (US) | 1986-06-24 | — | — | US | disclosed |
| EP-0183492-A1 | Substituted imidazole derivatives and their preparation and use | Farmos-Yhtyma Oy (FI) | 1986-06-04 | — | — | EP | disclosed |
| EP-0121830-A2 | Substituted dipeptides as antihypertensives | USV PHARMACEUTICAL CORPORATION (US) | 1984-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260080976-A1 | SYSTEM AND METHODS FOR GENERATION OF FRAGMENT MODULE LIBRARIES FOR LEAD OPTIMIZATION OF PHARMACEUTICALLY ACTIVE MOLECULES | BACE2, ADAM33, SET | IDO1 3262/4885PLAU 395/4885ANPEP 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.